Myostatin Inhibits Vascular Smooth Muscle Cell Proliferation and Local 14q32 microRNA Expression, But Not Systemic Inflammation or Restenosis.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
15 May 2020
Historique:
received: 14 04 2020
revised: 06 05 2020
accepted: 08 05 2020
entrez: 21 5 2020
pubmed: 21 5 2020
medline: 11 2 2021
Statut: epublish

Résumé

Myostatin is a negative regulator of muscle cell growth and proliferation. Furthermore, myostatin directly affects the expression of 14q32 microRNAs by binding the 14q32 locus. Direct inhibition of 14q32 microRNA miR-495-3p decreased postinterventional restenosis via inhibition of both vascular smooth muscle cell (VSMC) proliferation and local inflammation. Here, we aimed to investigate the effects of myostatin in a mouse model for postinterventional restenosis. In VSMCs in vitro, myostatin led to the dose-specific downregulation of 14q32 microRNAs miR-433-3p, miR-494-3p, and miR-495-3p. VSMC proliferation was inhibited, where cell migration and viability remained unaffected. In a murine postinterventional restenosis model, myostatin infusion did not decrease restenosis, neointimal area, or lumen stenosis. Myostatin inhibited expression of both proliferation marker PCNA and of 14q32 microRNAs miR-433-3p, miR-494-3p, and miR-495-3p dose-specifically in cuffed femoral arteries. However, 14q32 microRNA expression remained unaffected in macrophages and macrophage activation as well as macrophage influx into lesions were not decreased. In conclusion, myostatin did not affect postinterventional restenosis. Although myostatin inhibits 14q32 microRNA expression and proliferation in VSMCs, myostatin had no effect on macrophage activation and infiltration. Our findings underline that restenosis is driven by both VSMC proliferation and local inflammation. Targeting only one of these components is insufficient to prevent restenosis.

Identifiants

pubmed: 32429150
pii: ijms21103508
doi: 10.3390/ijms21103508
pmc: PMC7278907
pii:
doi:

Substances chimiques

MicroRNAs 0
Myostatin 0
Proliferating Cell Nuclear Antigen 0
RNA, Messenger 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Austrian Science Fund FWF
ID : M 2578
Pays : Austria
Organisme : Austrian Science Fund
ID : M2578-B30

Références

J Cell Physiol. 1999 Jul;180(1):1-9
pubmed: 10362012
N Engl J Med. 2003 Oct 2;349(14):1315-23
pubmed: 14523139
Ann Surg. 2015 Nov;262(5):841-7; discussion 847-8
pubmed: 26583674
PLoS One. 2017 Oct 10;12(10):e0185820
pubmed: 29016683
Biomaterials. 2005 Sep;26(26):5386-94
pubmed: 15814137
Expert Rev Cardiovasc Ther. 2016;14(1):87-104
pubmed: 26567863
Circ Res. 2014 Sep 26;115(8):696-708
pubmed: 25085941
Science. 2002 May 24;296(5572):1486-8
pubmed: 12029139
Circulation. 2018 Nov 27;138(22):2545-2558
pubmed: 30571345
Circulation. 2001 Sep 4;104(10):1188-93
pubmed: 11535578
Heart. 2007 Aug;93(8):922-7
pubmed: 17449502
Cardiovasc Res. 2005 Dec 1;68(3):415-24
pubmed: 16023630
Sci Rep. 2017 Apr 13;7:46362
pubmed: 28406165
J Hered. 2011 Jan-Feb;102(1):94-101
pubmed: 20817761
Front Cardiovasc Med. 2019 Aug 08;6:113
pubmed: 31440517
Nature. 1997 May 1;387(6628):83-90
pubmed: 9139826
Ann Surg. 2013 Nov;258(5):743-51; discussion 752-3
pubmed: 24096771
J Pathol. 2004 Aug;203(4):861-70
pubmed: 15258987
N Engl J Med. 2004 Jan 15;350(3):221-31
pubmed: 14724301
Oncotarget. 2017 Jan 24;8(4):5943-5953
pubmed: 27992376
Atherosclerosis. 2017 Jun;261:26-36
pubmed: 28445809
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
J Vasc Interv Radiol. 2001 Jan;12(1):79-88
pubmed: 11200358
Eur Heart J. 2011 Nov;32(22):2851-906
pubmed: 21873417
J Clin Invest. 1998 Mar 15;101(6):1225-32
pubmed: 9502763
Rev Esp Cardiol (Engl Ed). 2015 Dec;68(12):1125
pubmed: 26675199
Circ Res. 2000 Aug 4;87(3):248-53
pubmed: 10926877
Cardiovasc Res. 2016 May 1;110(1):6-22
pubmed: 26912672
Atherosclerosis. 2007 Aug;193(2):335-42
pubmed: 17087966
Eur Heart J. 2020 Jan 14;41(3):407-477
pubmed: 31504439
Nat Rev Cardiol. 2011 Sep 13;9(1):53-62
pubmed: 21912414
Diabetes. 2009 May;58(5):1133-43
pubmed: 19208906
Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1960-9
pubmed: 22652603
Endocr J. 2008 Mar;55(1):11-21
pubmed: 17878607
Catheter Cardiovasc Interv. 2013 Jan 1;81(1):E23-8
pubmed: 22431239

Auteurs

Eveline A C Goossens (EAC)

Department of Surgery, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Einthoven Laboratory for Experimental Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

Margreet R de Vries (MR)

Department of Surgery, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Einthoven Laboratory for Experimental Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

J Wouter Jukema (JW)

Department of Cardiology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

Paul H A Quax (PHA)

Department of Surgery, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Einthoven Laboratory for Experimental Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.

A Yaël Nossent (AY)

Department of Surgery, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Einthoven Laboratory for Experimental Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.
Department of Internal Medicine II, Medical University of Vienna, 1090 Vienna, Austria.
Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH